Prostate cancer trials in Japan
43 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- Where
- Tokyo
- Age
- 18 years and over
- People
- 54 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07332455 - Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Akita, Asahikawa, Fukuoka, Fukushima, Gifu, Hirakata, Hiroshima, Kagoshima, Kashihara, Kita, Kitakyushu, Kobe, Kumamoto, Kurume, Minato, Miyazaki, Mukai-awagasaki, Nagano, Ōita, Ōmura, Saga, Sakai, Sakura, Sapporo, Shimajiri, Suita, Tōon, Yokohama
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - No phaseTaking peopleA Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
- Where
- Many Locations
- Age
- 18 years and over
- People
- 100
- Run by
- Bayer
See details and how to joinNCT06661122 - Phase 3Taking peopleDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- Where
- Osaka, Tokyo
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 1Enrolling by invitationA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Nagoya, Tokyo
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 1Taking peopleA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Chiba, Kyoto, Osaka
- Age
- 18 years and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - Phase 1Taking peopleA Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Where
- Tokyo
- Age
- 18 years and over
- People
- 355 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06095089 · EU 2023-504063-17-00 - Phase 3Taking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama, Meguro-Ku, Sakura, Sapporo, Yokohama, Yokosuka
- Age
- 18 years and over
- People
- 1,203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - Phase 3Taking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto-gun, Yokohama
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - Phase 2Taking peopleA Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Where
- Kobe
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07832292 - Phase 3Taking peopleA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Chiba, Fukuoka, Kanazawa, Kashiwa, Kobe, Kumamoto, Matsuyama, Osaka, Sapporo, Shinjuku-ku, Suita, Yamagata, Yokohama, Yokosuka
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 3Taking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Chūō, Fukuoka, Gifu, Ginowan, Hamamatsu, Hiroshima, Kagoshima, Kahoku-gun, Kamakura, Kitakyushu, Kobe, Koshigaya, Kumamoto, Kurume, Kyoto, Minato, Nagano, Nagasaki, Nagoya, Niigata, Sakai, Sakura, Sapporo, Shinjuku, Tokushima, Tōon, Ube, Yufu
- Age
- 18 years and over
- People
- 1,440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - Phase 1/2Taking peopleStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Where
- Kyoto
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07288359 - Phase 1/2Taking peopleStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1Taking peopleA Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Where
- Kashiwa-shi, Kobe, Kōtoku, Sakura-shi
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07244341 · EU 2025-522512-16-00 - Phase 1/2Taking peopleA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Where
- Chuo Ku, Koto-ku
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07730021 · EU 2026-525938-31-00 - Phase 1Taking peopleA Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Where
- Hirakata
- Age
- 18 years and over
- People
- 208 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07570979 - Phase 1/2Taking peopleStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Chūōku, Kashiwa, Kōtoku
- Age
- 18 years to 130 years
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - Phase 2Taking peopleStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Where
- Chuo Ku, Kashiwa, Nagoya, Yokohama
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Pfizer
See details and how to joinNCT04606446 - Phase 3Taking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Chuo Ku, Fukuoka, Fukushima, Ishikawa, Kashiwa, Kobe, Kyoto, Sapporo, Yokohama
- Age
- 18 years to 100 years
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - Phase 3Taking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Akita, Eiheiji-cho,Yoshida-gun, Fukuoka, Fukushima, Gifu, Hirakata, Hiroshima, Kagoshima, Kashihara, Kita, Kitakyushu, Kobe, Kumamoto, Minato, Miyazaki, Mukai-awagasaki, Nagano, Ōita, Ōmura, Saga, Sakai, Sakura, Sapporo, Shimajiri, Suita, tabashi City, Tsu, Yokohama
- Age
- 18 years and over
- People
- 1,314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - Phase 3Taking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Bunkyo-ku, Fukuoka, Hidaka-shi, Kanazawa, Kita-gun, Kobe, Koshigaya-shi, Koto-ku, Matsuyama, Minato-ku, Nagoya, Osaka, Sagamihara-shi, Suita-shi, Toyama
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - Phase 3Taking peopleAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe, Kyoto, Sapporo, Suita-shi, Yokohama
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110